What is OCO Biomedical?
Established in 1977, OCO Biomedical has cultivated a reputation for excellence in the design and production of comprehensive dental implant solutions. The company operates at the intersection of medical device manufacturing and clinical education, providing practitioners with high-quality prosthetic components and regenerative materials. Their commitment to user-friendly technology and rigorous quality standards has allowed them to maintain a significant footprint in the United States market. By integrating advanced engineering with practical clinical applications, OCO Biomedical serves as a critical partner for dental professionals aiming to improve patient outcomes through reliable restorative procedures.
How much funding has OCO Biomedical raised?
OCO Biomedical has raised a total of $410K across 2 funding rounds:
Debt
$150K
Debt
$260K
Debt (2020): $150K with participation from PPP
Debt (2021): $260K led by PPP
Key Investors in OCO Biomedical
PPP
Public-Private Partnership
What's next for OCO Biomedical?
With the successful acquisition of this late-stage capital, OCO Biomedical is poised to accelerate its operational growth and solidify its industry standing. The strategic roadmap likely involves scaling production capacity to meet rising global demand for dental implants while simultaneously investing in next-generation regenerative product lines. Furthermore, the company is expected to expand its educational outreach, reinforcing its role as a thought leader in dental implantology. As the firm navigates this growth phase, the focus will remain on maintaining the high-quality standards that have defined its four-decade history, ensuring that its technological advancements continue to set benchmarks for the broader dental health sector.
See full OCO Biomedical company page
